Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

This study evaluates the quantile-aggregation method using both simulated data and publicly available Alzheimer disease randomized trial data.

Key findings

Why it matters

This study looks at a statistical method for combining results in Alzheimer disease trials, using simulated data and existing trial data. It does not test any treatment in patients, so it does not show whether any therapy works.

Study details

How this study scored 58/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 1 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 58 of 100.58 of 100 points earned42 not earned

Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA Neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomised controlled trial
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 10.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Sarah F. Ackley: h-index 22 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42149605)
Free to read 2 / 2 Free to read
Total 58 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Flanders, M. D., Caunca, M., La Joie, R., Schneider, L. S. S., & Ackley, S. F. (2026). Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.1240

Vancouver

Flanders MD, Caunca M, La Joie R, Schneider LSS, Ackley SF. Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.1240. PMID: 42149605.

BibTeX

@article{flanders2026-42149605,
  author  = {Flanders, Michael D. and Caunca, Michelle and La Joie, Renaud and Schneider, Lon S. S. and Ackley, Sarah F.},
  title   = {{Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials}},
  journal = {JAMA Neurology},
  year    = {2026},
  doi     = {10.1001/jamaneurol.2026.1240},
  pmid    = {42149605},
  url     = {https://doi.org/10.1001/jamaneurol.2026.1240}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments

Similar studies

More on Treatments

See all studies in Treatments →